Alopecia

Happy Head's StrandIQ system revolutionizes hair loss treatment with personalized genetic analysis, enhancing hair growth and scalp health for individuals.

Explore the latest breakthroughs in treatment and research during Hair Loss Awareness Month, enhancing understanding and patient care for hair loss disorders.

Research highlights that educational videos on standardized clinical photography protocols significantly lead to better management and treatment outcomes for patients with alopecia.

Key regulatory milestones for MAL-838, a novel sCD83-based, hormone-free hair growth ingredient, are paving the way for the market launch of a microbiome-friendly 8T3 product line.

In this exclusive Q&A, Alan J. Bauman, MD, shares expert insights on innovative hair loss treatments, early intervention strategies, and the future of alopecia care.

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.

Nektar Therapeutics advances alopecia areata treatment with FDA's Fast Track designation for rezpegaldesleukin, targeting immune modulation in chronic hair loss.

A first-of-its-kind study reveals artificial intelligence (AI)-driven insights on hair loss trends, highlighting the impact of genetics, hormones, and COVID-19 on alopecia.

Sun Pharmaceuticals has launched deuruxolitinib (Leqselvi) in the US, offering a new treatment for adults with severe alopecia areata.

A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

PP405 shows promise for hair regrowth in phase 2a trial, with 31% seeing >20% density increase; phase 3 studies are planned for 2026.

Subgroups more likely to respond included women and those with shorter-duration, less-extensive hair loss.

In a real-world study, the combination of Cuticapil stem hair serum and minoxidil reduced shedding and improved hair density.

Explore the significant mental health and socioeconomic impacts of atopic dermatitis and alopecia areata, revealing urgent needs for better support and awareness.

A 10-year study reveals azathioprine's impressive 93% hair regrowth rate in patients with moderate to severe alopecia, highlighting its long-term efficacy and safety.

In a new study, AI-driven personalized treatments significantly enhanced hair growth and scalp health, offering innovative solutions for hair loss management.

Significant unmet needs were found among high-quality validation studies on the internal structure of PROMs specific to alopecia areata.

A novel electrotrichogenic device shows promising results in promoting dense, thickened hair growth for male androgenetic alopecia patients.

The developement of bempikibart offers hope for effective treatment of severe alopecia areata amid unmet medical needs.

The innovative 21-item Hair & Scalp CARE questionnaire is designed to evaluate the psychological impact of hair and scalp conditions on quality of life.